Cargando…

OR26-02 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED), Binds To A Distinct Epitope From Teprotumumab

Disclosure: V. Bedian: Employee; Self; Viridian Therapeutics Inc. J.C. Tsai: Employee; Self; Viridian Therapeutics Inc. R.N. Newell: Employee; Self; Viridian Therapeutics Inc. Y. Zhao: Employee; Self; Viridian Therapeutics Inc. Introduction: VRDN-001, a full antagonist antibody to IGF-1 receptor (IG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bedian, Vahe, Tsai, Jordan C, Newell, Rachel N, Zhao, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554507/ http://dx.doi.org/10.1210/jendso/bvad114.2051

Ejemplares similares

FRI546 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED): Pharmacodynamic Responses In Healthy Volunteers And Patients With Active TED
por: Foster, Kelly, et al.
Publicado: (2023)

FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study
por: Douglas, Raymond, et al.
Publicado: (2023)

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)
por: Xin, Yan, et al.
Publicado: (2020)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

FRI554 Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab
por: Marta Niedzialkowska, Ewelina, et al.
Publicado: (2023)

SAT471 Hearing-Related Adverse Events in Teprotumumab Oncology Clinical Trials
por: Smith, Terry J, et al.
Publicado: (2023)

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

Rapidly Progressive Cognitive Decline and Varicella Zoster Blisters Associated With Teprotumumab in 2 Patients With Graves’ Orbitopathy
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

PSAT355 A Case Report Identifying Graves’ Ophthalmopathy in a Myasthenia Gravis Crisis and Response to Teprotumumab
por: Zia, Abdul, et al.
Publicado: (2022)

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
por: Douglas, Raymond S, et al.
Publicado: (2022)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

OR26-01 A Novel Small Molecule Thyrotropin Receptor Antagonist
por: Kahaly, George Jean, et al.
Publicado: (2023)

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials
por: Kahaly, George J, et al.
Publicado: (2023)

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)

OR26-03 Treatment With Linsitinib, An IGF-1 Receptor Inhibitor, Prevents Disease Development And Progression In An Experimental Model Of Thyroid Eye Disease
por: Gulbins, Anne, et al.
Publicado: (2023)

TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist
por: Chen, Hong, et al.
Publicado: (2015)

OR32-02 Thyroid Cancer Polygenic Risk Score Improves Risk Stratification Of Thyroid Nodules When Added To Ultrasound Imaging
por: Pozdeyev, Nikita, et al.
Publicado: (2023)

OR14-02 The Thyroid Hormone Analogs DITPA And TRIAC Triggered T3-signalling In Human MCT8-deficient Brain Organoids
por: Salas Lucia, Federico, et al.
Publicado: (2023)

OR26-05 Long-term Mortality And Cardiometabolic Effects Of Treatment For Hyperthyroidism: EGRET Study
por: Torlinska, Barbara, et al.
Publicado: (2023)

OR21-02 Impact of Nodule Size on the Probability of Hurthle Cell Carcinoma and Other Cancers in Thyroid Nodules with Multiple Chromosomal Copy Number Alterations
por: Nikiforova, Marina N, et al.
Publicado: (2020)

OR26-06 Cardiovascular Morbidity And Mortality In Patients With Resistance to THYROID Hormone (RTH): A Linked Record Study
por: Okosieme, Onyebuchi, et al.
Publicado: (2023)

Test de esperanza-desesperanza (TED TED-R) /
por: Pereyra Lavandina, Marío Ramón
Publicado: (2014)

FRI538 Discovery And Characterization Of Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonists For The Treatment Of Graves’ Disease
por: Fowler, Melissa A, et al.
Publicado: (2023)

SAT535 ANKRD26-RET Fusion Positive Metastatic Papillary Thyroid Carcinoma - Advanced Presentation of a Rare Mutation
por: Hashmi, Hiba, et al.
Publicado: (2023)

RF11 | PMON26 A Lump By Any Other Name: A Case of Diffuse Large B Cell Lymphoma of the Thyroid
por: Farghani, Saima, et al.
Publicado: (2022)

Ted Kennedy
por: David, Lester
Publicado: (1974)

Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
por: Qu, Xiao, et al.
Publicado: (2017)

Teprotumumab for Treatment of Pretibial Myxedema
por: Reyes, Michelangelo P, et al.
Publicado: (2023)

A Grave Initial Presentation of Graves’ Disease in a Patient With Moyamoya
por: Clutter, Courtney, et al.
Publicado: (2021)

FRI553 ICI-induced Thyroid Ophthalmopathy With De Novo Graves’ Disease
por: Moctezuma, Sananda I, et al.
Publicado: (2023)

SUN-511 Thyroid Storm Caused by Subacute Thyroiditis in a Patient with Methicillin-Resistant Staphylococcus Aureus Septicemia
por: Assaad, Mansur, et al.
Publicado: (2020)

Thyroid dermopathy responds to teprotumumab therapy
por: Crespo-Trevino, Ricaurte, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_quaen5bjl8o5e2u1uoooe52d17